Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

13.81 +0.04 (+0.29%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 10, 2026 Add to My Watchlist

Price and Volume

Volume	147,588
Open	13.73
Bid (Size)	12.00 (1,000)
Ask (Size)	16.80 (200)
Prev. Close	13.77
Today's Range	13.64 - 13.86
52wk Range	6.450 - 17.15
Shares Outstanding	21,055,392
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Today 16:01 EDT

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus

June 23, 2026

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Performance

YTD	-4.2%	-4.2%
1 Month	+0.8%	+0.8%
3 Month	-10.7%	-10.7%
6 Month	-0.1%	-0.1%
1 Year	+112.8%	+112.8%

More News

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

June 18, 2026

From Enanta Pharmaceuticals, Inc.

Via Business Wire

ENANTA PHARMACEUTICALS INC (NASDAQ:ENTA) Q2 Results: Narrower Losses, Clinical Milestones in Focus ↗

May 11, 2026

Via Chartmill

Enanta Pharmaceuticals (NASDAQ:ENTA) Beats Q1 Estimates, Reaffirms Cash Runway Into 2029 ↗

February 09, 2026

Via Chartmill

What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year ↗

May 30, 2026

Via The Motley Fool

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 28, 2026

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026

May 11, 2026

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

May 04, 2026

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

April 13, 2026

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026

April 07, 2026

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)

March 30, 2026

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference

March 03, 2026

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting

February 10, 2026

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025

February 09, 2026

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook

January 08, 2026

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Reports Mixed Q4 and Full-Year 2025 Results ↗

November 17, 2025

Via Chartmill

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

November 17, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Earnings Scheduled For November 17, 2025 ↗

November 17, 2025

Via Benzinga

Enanta Pharma's Earnings: A Preview ↗

November 14, 2025

Via Benzinga

This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday ↗

November 14, 2025

Via Benzinga

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

November 04, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

October 20, 2025

From Enanta Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 16, 2025

Via Benzinga

Frequently Asked Questions

Is Enanta Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Enanta Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Enanta Pharmaceuticals, Inc. - Common Stock trade on?

Enanta Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Enanta Pharmaceuticals, Inc. - Common Stock is ENTA on the Nasdaq Stock Market

What is the current price of Enanta Pharmaceuticals, Inc. - Common Stock?

The current price of Enanta Pharmaceuticals, Inc. - Common Stock is 13.81

When was Enanta Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Enanta Pharmaceuticals, Inc. - Common Stock was at 08/10/26 04:00 PM ET

What is the market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Enanta Pharmaceuticals, Inc. - Common Stock is 290.77M

How many shares of Enanta Pharmaceuticals, Inc. - Common Stock are outstanding?

Enanta Pharmaceuticals, Inc. - Common Stock has 291M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.